FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003060397> ?p ?o ?g. }

• W2003060397 endingPage "1655" @default.
• W2003060397 startingPage "1647" @default.
• W2003060397 abstract "ObjectivesAcute acquired hypofibrinogenemia in children undergoing cardiac surgery is a major concern because it often results in perioperative bleeding and high rates of allogeneic blood transfusion. Fibrinogen concentrate has been proposed as an alternative to cryoprecipitate (the gold standard therapy), with minimal infectious and immunologic risks. Our objective was to investigate the efficacy and safety of fibrinogen concentrate in children undergoing cardiac surgery.MethodsIn this randomized pilot study, patients were allocated to receive fibrinogen concentrate (60 mg/kg) or cryoprecipitate (10 mL/kg) if bleeding was associated with fibrinogen levels <1 g/dL after cardiopulmonary bypass weaning. The primary outcome was postoperative blood losses during the 48 hours after surgery.ResultsA total of 63 patients were included in the study, 30 in the fibrinogen concentrate group and 33 in the cryoprecipitate group. The median 48-hour blood loss was not significantly different between the 2 groups (320 mL [interquartile range, 157-750] vs 410 mL [interquartile range, 215-510], respectively; P = .672). After treatment, plasma fibrinogen concentration increased similarly following administration of both products. There were no differences in allogeneic blood transfusion after intervention treatment.ConclusionsA large trial comparing fibrinogen concentrate and cryoprecipitate in the management of children with acute acquired hypofibrinogenemia during heart surgery is feasible. The preliminary results of our study showed that the use of fibrinogen concentrate was as efficient and safe as cryoprecipitate in the management of bleeding children undergoing cardiac surgery. Acute acquired hypofibrinogenemia in children undergoing cardiac surgery is a major concern because it often results in perioperative bleeding and high rates of allogeneic blood transfusion. Fibrinogen concentrate has been proposed as an alternative to cryoprecipitate (the gold standard therapy), with minimal infectious and immunologic risks. Our objective was to investigate the efficacy and safety of fibrinogen concentrate in children undergoing cardiac surgery. In this randomized pilot study, patients were allocated to receive fibrinogen concentrate (60 mg/kg) or cryoprecipitate (10 mL/kg) if bleeding was associated with fibrinogen levels <1 g/dL after cardiopulmonary bypass weaning. The primary outcome was postoperative blood losses during the 48 hours after surgery. A total of 63 patients were included in the study, 30 in the fibrinogen concentrate group and 33 in the cryoprecipitate group. The median 48-hour blood loss was not significantly different between the 2 groups (320 mL [interquartile range, 157-750] vs 410 mL [interquartile range, 215-510], respectively; P = .672). After treatment, plasma fibrinogen concentration increased similarly following administration of both products. There were no differences in allogeneic blood transfusion after intervention treatment. A large trial comparing fibrinogen concentrate and cryoprecipitate in the management of children with acute acquired hypofibrinogenemia during heart surgery is feasible. The preliminary results of our study showed that the use of fibrinogen concentrate was as efficient and safe as cryoprecipitate in the management of bleeding children undergoing cardiac surgery." @default.
• W2003060397 created "2016-06-24" @default.
• W2003060397 creator A5006188476 @default.
• W2003060397 creator A5015757421 @default.
• W2003060397 creator A5040325029 @default.
• W2003060397 creator A5041179089 @default.
• W2003060397 creator A5047204622 @default.
• W2003060397 creator A5055785476 @default.
• W2003060397 creator A5063045235 @default.
• W2003060397 creator A5073578820 @default.
• W2003060397 creator A5074443384 @default.
• W2003060397 creator A5079909280 @default.
• W2003060397 date "2014-10-01" @default.
• W2003060397 modified "2023-10-16" @default.
• W2003060397 title "Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial" @default.
• W2003060397 cites W1484771525 @default.
• W2003060397 cites W1586397050 @default.
• W2003060397 cites W1651178925 @default.
• W2003060397 cites W1966383370 @default.
• W2003060397 cites W1995955953 @default.
• W2003060397 cites W2012863747 @default.
• W2003060397 cites W2013856778 @default.
• W2003060397 cites W2031032188 @default.
• W2003060397 cites W2033421420 @default.
• W2003060397 cites W2050544261 @default.
• W2003060397 cites W2052847754 @default.
• W2003060397 cites W2061786051 @default.
• W2003060397 cites W2062474169 @default.
• W2003060397 cites W2068086215 @default.
• W2003060397 cites W2080347790 @default.
• W2003060397 cites W2093059783 @default.
• W2003060397 cites W2102869383 @default.
• W2003060397 cites W2121864664 @default.
• W2003060397 cites W2123086946 @default.
• W2003060397 cites W2126091538 @default.
• W2003060397 cites W2126177654 @default.
• W2003060397 cites W2156287593 @default.
• W2003060397 cites W2160743149 @default.
• W2003060397 cites W2165111558 @default.
• W2003060397 cites W2168965844 @default.
• W2003060397 cites W2169455954 @default.
• W2003060397 cites W88689768 @default.
• W2003060397 doi "https://doi.org/10.1016/j.jtcvs.2014.04.029" @default.
• W2003060397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24951020" @default.
• W2003060397 hasPublicationYear "2014" @default.
• W2003060397 type Work @default.
• W2003060397 sameAs 2003060397 @default.
• W2003060397 citedByCount "75" @default.
• W2003060397 countsByYear W20030603972014 @default.
• W2003060397 countsByYear W20030603972015 @default.
• W2003060397 countsByYear W20030603972016 @default.
• W2003060397 countsByYear W20030603972017 @default.
• W2003060397 countsByYear W20030603972018 @default.
• W2003060397 countsByYear W20030603972019 @default.
• W2003060397 countsByYear W20030603972020 @default.
• W2003060397 countsByYear W20030603972021 @default.
• W2003060397 countsByYear W20030603972022 @default.
• W2003060397 countsByYear W20030603972023 @default.
• W2003060397 crossrefType "journal-article" @default.
• W2003060397 hasAuthorship W2003060397A5006188476 @default.
• W2003060397 hasAuthorship W2003060397A5015757421 @default.
• W2003060397 hasAuthorship W2003060397A5040325029 @default.
• W2003060397 hasAuthorship W2003060397A5041179089 @default.
• W2003060397 hasAuthorship W2003060397A5047204622 @default.
• W2003060397 hasAuthorship W2003060397A5055785476 @default.
• W2003060397 hasAuthorship W2003060397A5063045235 @default.
• W2003060397 hasAuthorship W2003060397A5073578820 @default.
• W2003060397 hasAuthorship W2003060397A5074443384 @default.
• W2003060397 hasAuthorship W2003060397A5079909280 @default.
• W2003060397 hasBestOaLocation W20030603971 @default.
• W2003060397 hasConcept C119060515 @default.
• W2003060397 hasConcept C126322002 @default.
• W2003060397 hasConcept C141071460 @default.
• W2003060397 hasConcept C168563851 @default.
• W2003060397 hasConcept C2778258694 @default.
• W2003060397 hasConcept C2778589496 @default.
• W2003060397 hasConcept C2778789114 @default.
• W2003060397 hasConcept C2778881276 @default.
• W2003060397 hasConcept C2779036427 @default.
• W2003060397 hasConcept C2780014101 @default.
• W2003060397 hasConcept C2910129229 @default.
• W2003060397 hasConcept C31174226 @default.
• W2003060397 hasConcept C42219234 @default.
• W2003060397 hasConcept C66112548 @default.
• W2003060397 hasConcept C71924100 @default.
• W2003060397 hasConcept C89560881 @default.
• W2003060397 hasConceptScore W2003060397C119060515 @default.
• W2003060397 hasConceptScore W2003060397C126322002 @default.
• W2003060397 hasConceptScore W2003060397C141071460 @default.
• W2003060397 hasConceptScore W2003060397C168563851 @default.
• W2003060397 hasConceptScore W2003060397C2778258694 @default.
• W2003060397 hasConceptScore W2003060397C2778589496 @default.
• W2003060397 hasConceptScore W2003060397C2778789114 @default.
• W2003060397 hasConceptScore W2003060397C2778881276 @default.
• W2003060397 hasConceptScore W2003060397C2779036427 @default.
• W2003060397 hasConceptScore W2003060397C2780014101 @default.
• W2003060397 hasConceptScore W2003060397C2910129229 @default.
• W2003060397 hasConceptScore W2003060397C31174226 @default.

• next